Assessing the Preparedness of the Australian Health Care System Infrastructure for an Alzheimer's Disease-Modifying Therapy
Sangita M. Baxi, Federico Girosi, Jodi L. Liu
2019
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer's Treatment
Jodi L. Liu, Jakub P. Hlavka, Daniel T. Coulter, Sangita M. Baxi, Soeren Mattke, Courtney A. Gidengil
2019
Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment
Jakub P. Hlavka, Soeren Mattke, Jodi L. Liu
2018
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the EU-5 Countries
Soeren Mattke, Andreas Ullrich and Mo Wang
2020
Assessing the Preparedness of the Japanese Health Care System Infrastructure for an Alzheimer’s Treatment
Soeren Mattke, Jakub P. Hlávka, Joanne Yoong, Mo Wang, Rei Goto
2019
Assessing the Preparedness of the Korean Healthcare System Infrastructure for an Alzheimer’s Treatment
Hankyung Jun, Sang Kyu Cho, Joanne Yoong, Soeren Mattke
2020
Assessing the Preparedness of the Taiwanese Healthcare System Infrastructure for an Alzheimer’s Treatment
Hankyung Jun, Sang Kyu Cho, Joanne Yoong, Oliver Yuen, Soeren Mattke
2021
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in the United States
Soeren Mattke and Mo Wang
2020
Implications of Alzheimer’s Treatment for Organization and Payment of Medical Practices in Canada
Soeren Mattke and Mo Wang
2021
Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment
Jenny Lam, Hankyung Jun, Sang Kyu Cho, Mark Hanson, Soeren Mattke
2021
Estimating minimal clinically important differences for two scales in patients with chronic traumatic brain injury
Soeren Mattke, Steven C. Cramer, Mo Wang, Janet Prvu Bettger, Kevin M.Cockroft, Wuwei Feng, Michael Jaffee, Tolu O. Oyesanya, Ava M. Puccio,Nancy Temkin, Carolee Winstein, Steven L. Wolf, and Michael R. Yochelson
2020
Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: Projecting the impact on the cost and wait times
Soeren Mattke, Sang Kyu Cho, Tobias Bittner, Jakub Hlávka, Mark Hanson
2020
How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Hankyung Jun, Sang K Cho, Elmar R Aliyev, Soeren Mattke, Sze-Chuan Suen
2020
The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia
Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Antoine C El Khoury, Soeren Mattke
2019
The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey
Jenny Lam, Jakub Hlávka and Soeren Mattke
2019
Evidence for Misspecification of a Nationally Used Quality Measure for Substance Use Treatment
Soeren Mattke, Zachary Predmore, Elizabeth Sloss, Asa Wilks, Katherine E Watkins
2018
Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia
Marcela Horvitz-Lennon, Zachary Predmore, Patrick Orr, Mark Hanson, Richard Hillestad, Mike Durkin, Edward Kim, Soeren Mattke
2018
Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia